Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females
A Single-Dose, Open-Label, Parallel Group Study To Evaluate The Pharmacokinetics And Safety Profile Of PROELLEX® (CDB-4124) In Female Subjects With Various Stages Of Impaired Renal Function And In Healthy Female Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33014-3616
- Clinical Pharmacology of Miami, Inc
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55404
- DaVita Clinical Research
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- New Orleans Center For Clinical Research - Knoxville
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Speak, read, and understand English or Spanish and is willing and able to provide written informed consent on an IRB-approved form prior to the initiation of any study procedures;
- Female, between the ages of 18 and 48 years with Body Mass Index (BMI) between 18 and 39, inclusive, is preferred
- Subject must meet the criteria of mildly or moderately impaired renal function or have normal renal function
- Subject with renal impairment must have evidence of stable disease
- If on medications for treatment of the complications of renal disease, and other concommitant chronic illnesses, subject must have been taking the medications at a stable dose for at least 10 days prior to the first Proellex® dosing date and are then to be continued at the same dose for the duration of the study.
- Negative urine pregnancy test at screening visit
- Subject must agree to use a medically acceptable and effective non-hormonal double barrier method of birth control
- Healthy subject must have no significant abnormal findings at the screening physical examination
- Subject is willing to remain in the clinic for the screening visit (approximately 1 day for the first screening visit) and for the treatment visit (approximately 3 days)
- Additional inclusion criteria may apply
Exclusion Criteria:
- Abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant
- Subject with clinically significant abnormal liver function
- Pregnant or lactating females, or women who are attempting or expecting to become pregnant at any time during the study or one month after the study
- An acute illness within five (5) days of study medication administration
- Subject with diagnosed or suspected carcinoma of the breast, reproductive organs or any other organ system
- Additional exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 50 mg Proellex Mild impairment
50 mg Proellex single dose Female subjects with mild renal impairment function.
|
Single dose
Other Names:
|
|
Active Comparator: 50 mg Proellex Moderate
50 mg Proellex, Female subjects with moderate renal impairment function.
|
Single dose
Other Names:
|
|
Active Comparator: 50 mg Proellex, Normal
50 mg Proellex, Female subjects with normal renal function.
|
Single dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Cmax of Proellex
Time Frame: 48 hours
|
48 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Andre van As, MD, PhD, Repros Therapeutics Inc.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ZP-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.